Objective
Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T-cell receptors. In this respect, CARs are increasingly used for cellular therapy to redirect T-cells specifically towards killing of cancer cells. Recent success stories of cancer therapy with CAR modified T-cells have raised enormous scientific and public expectations to cure severely ill patients. However, there are still many obstacles to overcome for translation into clinics because the technology for GMP-compliant manufacture of genetically modified cellular products is extremely complex and expensive. Moreover, CAR therapy needs to be improved with respect to off-target activity, safety and potency. Consequently, the envisaged project is overall aiming at a particular technological breakthrough in cellular cancer therapy by delivering a comprehensive CARAT platform explicitly tailored for automated, easy-to-handle and cost-efficient manufacture of CAR-modified ATMP. Specifically, we aim:
(a) to implement unique next-generation cell processing tools like the CliniMACS Prodigy
(b) to develop advanced enabling technologies to obtain more effective and safer cellular products by improved gene delivery and innovative CARs design
(c) to assemble tools and technologies towards an integrated CARAT process for automated GMP-compliant manufacture of gene-modified T-cells
(d) to demonstrate proof-of-concept and regulatory compliance
(e) to disseminate broadly applicable, simplified CAR T-cell technologies
In summary, our vision is to overcome current hurdles for translation of cellular therapies and to elevate them to the next level of standard-of-care thus serving patients with so far incurable solid tumours and hematologic malignancies. Thereby, we will empower Europe to become a global leader in the development and commercialisation of CAR T-cell tools and technologies.
Fields of science
- engineering and technologymechanical engineeringmanufacturing engineering
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesclinical medicineoncology
- medical and health sciencesmedical biotechnologycells technologies
- natural sciencescomputer and information sciencessoftwaresoftware applications
Programme(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
51429 Bergisch Gladbach
Germany
See on map
Participants (8)
20132 Milano
See on map
63225 Langen
See on map
75654 Paris
See on map
WC1E 6BT London
See on map
CF10 4LN Cardiff
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
79106 Freiburg
See on map
66386 St Ingbert
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
51429 Bergish Gladbach